Novasys: Using Clinical Trials to Drive Adoption for Incontinence
Novasys Medical is using radio frequency (RF) energy to treat stress urinary incontinence in women. The company chose to adopt a much more rigorous and expensive clinical trials strategy than was needed to gain FDA approval of its device. This approach flummoxed the FDA,, slowing approval of the company's IRenessaI system. Novasys is betting that the enhanced data collected from its clinical study will result in the company gaining faster reimbursement that it hopes will drive adoption.
by Stephen Levin
Nowhere has the current increased concern of regulators and industry about the long-term safety of medical devices been reflected more...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.